Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been newly diagnosed with non-small cell lung cancer (a type of lung cancer) and are scheduled to receive a combination of chemotherapy, radiation therapy, and then an immunotherapy drug called durvalumab, following a specific treatment approach known as the PACIFIC trial protocol
- People who are willing to receive all their treatment and assessments at MD Anderson Cancer Center
- People who have a smartphone that can send data over Wi-Fi or a mobile data plan
- People who are able and willing to do a simple breathing test at home once a week, with no medical reasons preventing them from doing so
Who may not be able to join:
- No specific exclusion criteria were listed in the official criteria provided (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Development of pneumonitis during chemoradiotherapy and immunotherapy for locally advanced non-small cell lung cancer (NSCLC)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.